Jiro Kikuchi

Mechanistic and Clinical Differences Between Daratumumab and Isatuximab in Multiple Myeloma: Emerging Roles of 1q Gain and Immune Remodeling

Jiro Kikuchi, Hiroshi Yasui

Anti-CD38 monoclonal antibodies have substantially improved outcomes in multiple myeloma (MM). Although daratumumab and isatuximab target the same antigen, accumulating evidence indicates that they differ in epitope recognition, biological activity, and immunomodulatory properties, suggesting these agents may not be therapeutically interchangeable. This …

jp (code pays fourni par la source)

Structure-based prediction reveals a difference in the binding mode of anti-BCMA antibodies to BCMA and soluble BCMA

Jiro Kikuchi, Naoki Osada, Sae Matsuoka, Hiroshi Yasui et autres

jp (code pays fourni par la source)

Heart Failure With Preserved Ejection Fraction and Lower Natriuretic Peptide: Clinical Characteristics and Change in Natriuretic Peptide Levels

KANAKO TERAMOTO, Kotaro Nochioka, Yasuhiko Sakata, Kunihiro Nishimura et autres

BACKGROUND: Recent heart failure (HF) guidelines emphasize the importance of recognizing patients with mild elevations in NT-proBNP (N-terminal pro-B-type natriuretic peptide). While NT-proBNP is a key biomarker for diagnosing HF and predicting outcomes, its levels are often lower than expected in HF …

jp (code pays fourni par la source)

SETD7 is a novel therapeutic target for multiple myeloma with t(11;14)+

Jiro Kikuchi, Sae Matsuoka, Naoki Osada, Kazuki Yoshimura et autres

jp (code pays fourni par la source)

SETD7 is a Novel Therapeutic Target for Multiple Myeloma Carrying t(11;14)

Sae Matsuoka, Naoki Osada, Sho Ikeda, Naoto Takahashi et autres

FOXM1 down-regulation is a trigger of isatuximab-induced direct cell death in multiple myeloma cells with 1q+

Jiro Kikuchi, Naoki Osada, Sae Matsuoka, Hirotaka Kazama et autres

Not available.

jp, fr (code pays fourni par la source)

OP0283 NOVEL DISEASE ACTIVITY INDEX FOR ADULT STILL'S DISEASE USING MACHINE LEARNING WITH THREE PROTEINS: UTILITY UNDER IL-6 SIGNAL INHIBITION

Mauro Magi, Hiroto Yoshida, H. Tamai, Kazuma Matsumoto et autres

Background: Adult Still's disease (ASD) is a systemic inflammatory disorder that involves many inflammatory cytokines such as IL-6. Whereas tocilizumab (TCZ), an anti-IL-6 receptor antibody, has been shown to be effective for ASD, it suppresses serum CRP levels despite residual disease activity, …

us, jp (code pays fourni par la source)

Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+

Sae Matsuoka, Naoki Osada, 浩和 窪田, Ko Kikuzato et autres

jp, fi, no (code pays fourni par la source)

c-FOS Confers Stem Cell-like Features to Multiple Myeloma Cells in a Bone Marrow Microenvironment

Naoki Osada, Jiro Kikuchi, Sae Matsuoka, Hiroshi Yasui et autres

Multiple myeloma (MM) is the second most common hematologic malignancy and has a poor prognosis. Although the outcomes of MM have markedly improved with the approval of novel agents, the high incidence of relapse means that MM remains incurable. The bone marrow …

jp (code pays fourni par la source)

Discovery of a novel class NSD2 inhibitor for multiple myeloma with t(4;14)+

Sae Matsuoka, Naoki Osada, Hirokazu Kubota, Ko Kikuzato et autres

● RK-0080552 is a novel class NSD2 inhibitor that exerts specific cytotoxicity on MM cells carrying t(4;14) ● Down-regulation of IRF4 expression is the molecular basis and rationale for the anti-MM effect of RK-0080552 The prognosis for multiple myeloma (MM) has continued …

jp, no (code pays fourni par la source)

Cytotoxicity of bendamustine, alone and in combination with novel agents, toward adult T-cell leukemia cells

Naoki Osada, Jiro Kikuchi, Yosuke Okada, Sae Matsuoka et autres

Adult T-cell leukemia/lymphoma (ATL) develops from the infection of T cells with human T lymphotropic virus type 1 (HTLV-1). There are an estimated 5-20 million HTLV-1 carriers worldwide and the patients are frequently observed in subtropical Africa, the Caribbean, Middle East, South …

jp (code pays fourni par la source)

OA-35 Discovery of a Novel Class MMSET Inhibitor With Specificity for t(4; 14)-Positive Multiple Myeloma

Sae Matsuoka, Naoki Osada, Hirokazu Kubota, Ko Kikuzato et autres